Array Biopharma (ARRY) Misses Q3 EPS by 4c
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $7.77 +4.30%
EPS Growth %: -48.0%
Financial Fact:
Comprehensive loss: -28.6M
Today's EPS Names:
PLCE, COE, JVA, More
EPS Growth %: -48.0%
Financial Fact:
Comprehensive loss: -28.6M
Today's EPS Names:
PLCE, COE, JVA, More
Join SI Premium – FREE
Array Biopharma (NASDAQ: ARRY) reported Q3 EPS of ($0.16), $0.04 worse than the analyst estimate of ($0.12). Revenue for the quarter came in at $43 million versus the consensus estimate of $30.35 million.
For earnings history and earnings-related data on Array Biopharma (ARRY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS Reiterates Neutral Rating on Lennar (LEN) Following Q2 Results
- MIND Technology (MIND) Misses Q1 EPS by 5c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
